News Drug Development

Capstone Therapeutics Announces Initiation of Dosing for AZX100 Phase 2 Clinical Trial in Dermal Scarring; Management to Host Teleconference and Webcast Today

February 10, 2009 |

1 min read

TEMPE, Ariz., Feb. 10, 2009 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) announced today the initiation of dosing for its AZX100 Phase 2 clinical trial in dermal scarring.

Clinical research Phase II

MORE ON THIS TOPIC

Drug Development

Eroding Immunity: Vaccine Hesitancy and Cynicism With Paul Offit

May 8, 2025

·

1 min read

·

Computational Biology - The Study of Biological Systems Through Computational Techniques and Modeling - Conceptual Illustration

Gene therapy

CRISPR’s Casgevy on the Rise With More Gene Therapy Proof of Concept To Come in 2025

May 7, 2025

·

4 min read

·

Annalee Armstrong

Brain with pills, Alzheimer awareness day, dementia diagnosis, Parkinson disease, memory loss disorder, damaged mind

Huntington’s disease

PTC Nosedives Despite Claiming Phase II Win for Huntington’s Hopeful

May 5, 2025

·

2 min read

·

Dan Samorodnitsky

Vaccine and syringe injection. Doctor hand with syringe. Vaccination of people for prevention, immunization and treatment from virus infection. Medicine, flu shot, test with needle. Vector

Policy

HHS To Require Placebo-Controlled Trials for All New Vaccines in ‘Radical Departure’ From Past

May 1, 2025

·

3 min read

·

Heather McKenzie